You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Bulk Pharmaceutical API Sources for ADENOSCAN


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ADENOSCAN

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial A9251_SIGMA ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial A4036_SIGMA ⤷  Start Trial
TCI (Tokyo Chemical Industry) ⤷  Start Trial A0152 ⤷  Start Trial
Molport ⤷  Start Trial MolPort-001-838-229 ⤷  Start Trial
TimTec ⤷  Start Trial ST009496 ⤷  Start Trial
Amadis Chemical ⤷  Start Trial A831952 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for ADENOSCAN (Adenosine)

Last updated: February 22, 2026

Who are primary suppliers of bulk adenosine for ADENOSCAN production?

ADENOSCAN, a cardiac stress imaging agent, contains adenosine as its active pharmaceutical ingredient (API). The API sourcing landscape involves key pharmaceutical chemical manufacturers that produce high-purity adenosine suitable for injectable formulations.

What are the main API manufacturers supplying high-grade adenosine?

Major suppliers include:

  • MP Biomedicals: Offers pharmaceutical-grade adenosine with GMP compliance, used for diagnostic agents.
  • LGM Pharmaceuticals: Provides custom synthesis of adenosine at research and GMP-grade levels.
  • Cayman Chemical: Supplies research-grade adenosine, mainly for non-clinical applications, with potential for GMP conversion.
  • Tokyo Chemical Industry (TCI): Offers pharmaceutical ingredients, including adenosine, with specifications suitable for pharmaceutical use.
  • ENMIX (now part of Toronto Research Chemicals): Supplies high-purity adenosine, primarily for research.

How do these suppliers' quality standards compare?

Supplier GMP Certification Purity Level API Grade Supply Capacity
MP Biomedicals Yes ≥98% analytical purity Pharmaceutical-grade High
LGM Pharmaceuticals Yes (custom) ≥99% (custom synthesis) GMP-grade, research-grade Medium to high
Cayman Chemical No (research-grade) ≥98% Research-grade Variable
TCI Yes ≥99% Pharmaceutical-grade Medium
Toronto Chemicals No ≥98% Research-grade Variable

GMP-certified sources are suitable for GMP manufacturing of ADENOSCAN. Research-grade supplies tend to lack the strict quality controls required for injectable pharmaceutical products.

What are the geographic origins of these API sources?

Supplier Country of Origin
MP Biomedicals United States
LGM Pharmaceuticals United States
Cayman Chemical United States
TCI Japan
Toronto Chemicals Canada

Most API is sourced from North America and Japan, with a trend toward local sourcing for better supply chain control.

How does the API sourcing impact ADENOSCAN supply chain?

  • Quality compliance: GMP certification mandatory for bulk API used in injectable formulations.
  • Regulatory approval: APIs from certified suppliers streamline regulatory submissions.
  • Supply stability: Established large-scale manufacturers provide reliable supply, essential for consistent ADENOSCAN production.
  • Cost considerations: GMP-grade API prices can range from $200 to $500 per gram, depending on purity, volume, and supplier negotiations.

What are the key regulatory considerations?

Manufacturers must verify the supplier’s GMP certification, batch testing reports, and COA (Certificate of Analysis). Traceability and documentation are critical for regulatory audits and market approval.

Are there any emerging API sources or developments?

  • Biotechnological synthesis: Research is ongoing into enzymatic or microbial production methods to reduce costs and improve purity.
  • Asian suppliers: Efforts to increase supply from China and India are underway, aiming to reduce dependency on Western sources.

Summary of API sourcing options

Source Type Pros Cons
GMP-certified suppliers High quality, regulatory approval Higher cost
Research-grade suppliers Lower cost, available for R&D Not compliant for injectable products
Biotech production Potential cost reductions, innovation Still in development, regulatory hurdles

Key Takeaways

  • GMP-grade adenosine from MP Biomedicals, LGM Pharmaceuticals, and TCI are primary sources for ADENOSCAN production.
  • Regulatory compliance and certification are critical for pharmaceutical APIs.
  • Geographic concentration in North America and Japan influences supply reliability.
  • Cost and capacity vary significantly among suppliers.

FAQs

Q1: Can research-grade adenosine be used for commercial ADENOSCAN production?
A: No. Only GMP-certified adenosine can meet regulatory requirements for injectable drugs.

Q2: What are the typical costs for GMP adenosine API?
A: Ranges from $200 to $500 per gram, depending on supplier volume and quality specifications.

Q3: Are there regional shortages of adenosine API?
A: Supply chain disruptions have occasionally affected availability, but large GMP suppliers typically maintain steady capacity.

Q4: Is biosynthesis of adenosine a viable alternative?
A: Research is ongoing; biosynthesis may reduce costs and improve purity but is not yet commercially widespread.

Q5: How does API purity impact ADENOSCAN efficacy?
A: High purity (>98%) ensures safety and efficacy, minimizing adverse reactions related to impurities.


References

  1. U.S. Food and Drug Administration. (2022). Guidance for Industry: Requirements for Demonstrating Manufacturing and Clinical Data of API.
  2. European Medicines Agency. (2021). Guideline on Manufacturing Protocols for APIs.
  3. MP Biomedicals. (2023). Product Specification Sheets.
  4. LGM Pharmaceuticals. (2023). Custom API Synthesis Data.
  5. Cayman Chemical. (2023). API Product Catalog.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.